Oxular was acquired by Regeneron in January 2025. To continue following for updated information, please visit Regeneron’s LinkedIn. www.linkedin.com/company/regeneron-pharmaceuticals/ “One treatment a year. Life changing.” Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This unique combination aims to substantially improve Read more